Gilead Buying Liver Disease Drugmaker CymaBay For $4.3B

By Al Barbarino · February 12, 2024, 1:24 PM EST

Gilead Sciences Inc. said Monday that it has agreed to purchase liver disease-focused clinical-stage biopharmaceutical company CymaBay Therapeutics Inc. for $4.3 billion in cash....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Al

April 30, 2024
PE-Backed Medline Buying Ecolab's Surgical Unit For $950M
April 29, 2024
Deciphera Stock Soars On $2.4B Deal With Japan's Ono
April 24, 2024
Private Equity Lag Continues To Stunt M&A Growth
April 18, 2024
23andMe Taps Dechert To Review CEO Buyout Proposal
April 09, 2024
Tech M&A Reigns Supreme In Q1 After Rare Hiccup In Q4
April 05, 2024
Freshfields Reps J&J On $13.1B Deal For Shockwave Medical
March 25, 2024
Paul Weiss-Led AbbVie Inks Up To $212M Deal For Landos Bio
March 25, 2024
Kirkland Guides Ingersoll Rand On $2.3B ILC Dover Buy
March 19, 2024
IFF Selling Pharma Unit To French Co. Roquette In $2.85B Deal
February 05, 2024
Novo Holdings Buying Biopharma Co. Catalent In $16.5B Deal